Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2011-02-02

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 254

Registration Number: NCT01288326

Locations: 🇧🇪
Novo Nordisk Investigational Site, Brussels, Belgium

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: NNC 0128-0000-2011

First Posted Date: 2011-02-02

Last Posted Date: 2016-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01288391

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Completed

Conditions: Acquired Bleeding Disorder
Acquired Haemophilia

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2011-01-27

Last Posted Date: 2014-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01285089

Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC109-0012
Drug: placebo

First Posted Date: 2011-01-24

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 67

Registration Number: NCT01282255

Locations: 🇬🇧
Novo Nordisk Investigational Site, Norwich, United Kingdom

Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: metformin

First Posted Date: 2011-01-17

Last Posted Date: 2014-10-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 179

Registration Number: NCT01278160

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2011-01-10

Last Posted Date: 2015-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 96

Registration Number: NCT01272973

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2011-01-07

Last Posted Date: 2018-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3731

Registration Number: NCT01272219

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin glargine

First Posted Date: 2011-01-07

Last Posted Date: 2017-03-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 296

Registration Number: NCT01272193

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2011-01-07

Last Posted Date: 2017-12-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 846

Registration Number: NCT01272232

Locations: 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: NNC 0128-0000-2011
Drug: NNC 0128-0000-2021

First Posted Date: 2011-01-07

Last Posted Date: 2014-08-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 12

Registration Number: NCT01272206

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy